摘要
目的 :观察胸腺肽α1 联合促肝细胞生长素 (HGF)治疗慢性重症肝炎的疗效。方法 :慢性重症肝炎 6 4例 ,分成治疗组 2 4例 ,对照组 4 0例。对照组用 HGF等支持、保肝疗法 ;治疗组在此基础上加胸腺肽α1 ,观察疗效及病死率 ,3个月后检测血清总胆红素、谷丙转氨酶、凝血酶原时间、透明质酸等水平。结果 :治疗组总有效率为 75 .4 % ,病死率为 2 5 .0 % ;对照组总有效率为 4 5 .0 % ,病死率为 4 7.5 % ,两组比较差异有显著性意义 (P <0 .0 5 ) ;治疗组与对照组治疗前各项生化指标比较差异无显著性意义 (P >0 .0 5 ) ,治疗后两组生化指标均有所下降 ,两组比较差异有非常显著性意义 (P <0 .0 1)。结论 :胸腺肽α1 联合 HGF能显著减轻肝脏的损伤程度 ,降低病死率 ,而且患者耐受性好 。
Objective: To observe the therapeutic effect of thymosin α 1(T α l) combined with HGF in the treatment of chronic severe hepatitis.Methods: Sixty four patients with severe hepatitis, who were randomly divided into treatment group (n=24) and control group (n=40), received HGF for three months. Those in the treatment group received T α 1 coincidently. Three months later, the levels of serum TSB, ALT, HA and PT was measured. Results: At the end of treatment, the levels of TSB and ALT were decreased in the treatment group as compared with those in the ontrol group(P <0. 05). In the treatment group, total effective rate was 75.4% and the mortality was 25.0%, while that in the control group was 45.0% and 47. 5% respectively with the difference being significant (P <0. 05). Conclusion: The therapy of T α 1 combined with HGF can obviously alleviate the liver injury and decrease the mortality of the patients with chronic severe hepatitis.
出处
《中国中西医结合消化杂志》
CAS
2002年第1期31-32,共2页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
